VivaTech 2026: Scaling Artificial Intelligence in Healthcare to Deliver Faster for Patients

The impact of healthcare innovation is often invisible, but behind every treatment lies a long and complex path to bring a new medicine to patients. At Sanofi, our focus extends beyond the promise of AI as a technology: we focus on where it can create scalable impact today and in the future. Our scalable solutions embed migrate AI into the full value chain and medicine journey: from drug discovery and clinical development to manufacturing, supply forecasting, and patient support after launch. This approach creates a more connected ecosystem, where scientific progress is translated into operational execution faster and more reliably, accelerating the delivery of innovations that can improve patients’ lives.

And that strengthens our vision at VivaTech – introducing AI’s impact and inspiring cross-industry innovation across the ecosystem.

Along the way, visitors discover how Sanofi’s digital patient support solutions, scientific innovations, and AI-powered data tools work together to enhance understanding, care, and engagement, creating a more connected care experience. Starting from our AI Literature Review solution, it delivers more than 95% accuracy while dramatically reducing review times. As we accelerate the analysis of scientific evidence, we ensure insights are translated into actions. Meanwhile, our integrated ecosystem, IMMS, connects Sanofi directly with healthcare professionals and patients undergoing immunology treatments.

The traditional R&D journey — from discovery to patient delivery — can span more than a decade. To tackle the most persistent bottlenecks in our industry, Sanofi is embedding AI across the entire R&D value chain, accelerating the development of innovative treatments. This enables data-driven decisions at every stage, turning insights into action earlier and faster.

Highlighting a few of the initiatives that accelerates this journey - eStudy transforms trial design by analyzing multimodal data to simulate trials before they start. It predicts cycle times, optimizes patient burden, and identifies cost drivers upfront, generating efficient, patient-centric protocols with fewer amendments and faster enrollment. FUSION is our Model-Informed Drug Development platform that enables in-silico trials. Powered by Sanofi's disease biology models and clinical data, it aims to predict safety, efficacy, and trial outcomes informing critical Go/No-Go decision across the development lifecycle. When clinical data becomes available, ClinShow applies AI-enhanced review and validation to help teams analyze results more efficiently.

Breakthrough science only matters if it reaches patients reliably. Our Manufacturing & Supply teams partner directly with industrial sites across the network, building digital and AI solutions that put expert AI and agents in daily work.

Two pillars we highlight this year, diving into the shopfloor: BEAM streamlines the transfer of new drugs or indications from R&D to industrial scale. Agility and innovation become the game changer that lets us launch medicines at an unprecedented pace. And Plasma strengthens the reliability of our equipment, continuity, and quality across production systems. This is what lets us deliver treatments to patients consistently, at scale. Together, they ensure that what we discover in the lab reaches the people who need it.

Scaling AI across a global organization requires more than technology. Behind this transformation are more than 70,000 Sanofians, empowered by AI to work faster, smarter, and more sustainably, with greater focus on improving patients’ daily lives. We are strengthening the foundations of this transformation ౼ from people and technology to lasting capabilities ౼ creating the conditions for innovation to scale across Sanofi worldwide.

AI Foundry, our internal platform powering AI development, enables data and AI builders to innovate responsibly at scale. Meanwhile, ETaOne, our AI-powered energy management platform, helps all Sanofians optimize consumption in real-time, improving efficiency while supporting our sustainability ambitions. And Concierge brings it all together: our internal AI companion helps everyone access the right information at the right time.

As AI moves from pilots to practice, responsibility becomes a prerequisite for scale. It builds trust in technology and serves as a strategic enabler to unlock the full potential of AI. To scale AI successfully, we believe it must be scaled with trust.

That principle is embedded across our responsible AI framework, RAISE (Responsible AI at Sanofi for Everyone). Through its five pillars ౼ responsibility, safety, fairness, transparency, and eco-consciousness ౼ we apply consistent standards across our AI adoption, our workforce, and our partner ecosystem. As we explore new frontiers, we remain guided by these pillars to balance innovation with the right safeguards. We will continue to share our journey and progress in responsibly scaling AI through articles on Sanofi.com.

Our AI journey is no longer defined by ambition alone, but by measurable impact across the value chain and patient journey. As VivaTech celebrates its 10^th anniversary, and Sanofi marks its 8^th year of participation, we are not only reflecting on how far AI has come today but looking ahead to what comes next: opening new possibilities by AI migration not just in the next 10 years, but in the next year!      We are helping to reshape a future where scientific breakthroughs bring greater value for patients around the world - not by Sanofi alone, but through our entire ecosystem and global partners.